JP4806124B2 - 乳癌の処置および診断のための組成物ならびにそれらの使用方法 - Google Patents

乳癌の処置および診断のための組成物ならびにそれらの使用方法 Download PDF

Info

Publication number
JP4806124B2
JP4806124B2 JP2000609567A JP2000609567A JP4806124B2 JP 4806124 B2 JP4806124 B2 JP 4806124B2 JP 2000609567 A JP2000609567 A JP 2000609567A JP 2000609567 A JP2000609567 A JP 2000609567A JP 4806124 B2 JP4806124 B2 JP 4806124B2
Authority
JP
Japan
Prior art keywords
seq
cdna sequence
determined cdna
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000609567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002540789A (ja
JP2002540789A5 (enExample
Inventor
チャン ユーチュー，
デイビン シー． ディロン，
ジェニファー リン ミッチャム，
チャンチュン シュ，
スーザン エル． ハーロッカー，
Original Assignee
コリクサ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/339,338 external-priority patent/US6573368B2/en
Priority claimed from US09/389,681 external-priority patent/US6518237B1/en
Priority claimed from US09/433,826 external-priority patent/US6579973B1/en
Application filed by コリクサ コーポレイション filed Critical コリクサ コーポレイション
Publication of JP2002540789A publication Critical patent/JP2002540789A/ja
Publication of JP2002540789A5 publication Critical patent/JP2002540789A5/ja
Application granted granted Critical
Publication of JP4806124B2 publication Critical patent/JP4806124B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000609567A 1999-04-02 2000-02-15 乳癌の処置および診断のための組成物ならびにそれらの使用方法 Expired - Fee Related JP4806124B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US09/285,480 1999-04-02
US09/285,480 US6590076B1 (en) 1999-04-02 1999-04-02 Compositions for the treatment and diagnosis of breast cancer and methods for their use
US09/339,338 US6573368B2 (en) 1998-12-28 1999-06-23 Compositions for the treatment and diagnosis of breast cancer and methods for their use
US09/339,338 1999-06-23
US09/389,681 US6518237B1 (en) 1998-12-28 1999-09-02 Compositions for treatment and diagnosis of breast cancer and methods for their use
US09/389,681 1999-09-02
US09/433,826 1999-11-03
US09/433,826 US6579973B1 (en) 1998-12-28 1999-11-03 Compositions for the treatment and diagnosis of breast cancer and methods for their use
PCT/US2000/005308 WO2000060076A2 (en) 1999-04-02 2000-02-15 Compositions for the treatment and diagnosis of breast cancer and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010125855A Division JP2010239970A (ja) 1999-04-02 2010-06-01 乳癌の処置および診断のための組成物ならびにそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2002540789A JP2002540789A (ja) 2002-12-03
JP2002540789A5 JP2002540789A5 (enExample) 2007-04-05
JP4806124B2 true JP4806124B2 (ja) 2011-11-02

Family

ID=27804894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000609567A Expired - Fee Related JP4806124B2 (ja) 1999-04-02 2000-02-15 乳癌の処置および診断のための組成物ならびにそれらの使用方法
JP2010125855A Pending JP2010239970A (ja) 1999-04-02 2010-06-01 乳癌の処置および診断のための組成物ならびにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010125855A Pending JP2010239970A (ja) 1999-04-02 2010-06-01 乳癌の処置および診断のための組成物ならびにそれらの使用方法

Country Status (5)

Country Link
US (2) US6590076B1 (enExample)
JP (2) JP4806124B2 (enExample)
AT (1) ATE514780T1 (enExample)
ES (1) ES2368899T3 (enExample)
ZA (1) ZA200108065B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647741B2 (en) * 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7414112B2 (en) * 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6774226B1 (en) * 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20040072185A1 (en) * 2000-09-15 2004-04-15 Patrizia Paterlini-Brechot Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses
US7560242B2 (en) * 2003-11-13 2009-07-14 The Burnham Institute Metadherin polypeptides, encoding nucleic acids and methods of use
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009155A1 (en) * 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 human secreted proteins
JP2002540761A (ja) * 1999-01-21 2002-12-03 アボット・ラボラトリーズ 乳房の疾患を検出するために有用な試薬と方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
ATE154698T1 (de) 1990-10-18 1997-07-15 Cellpro Inc Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
ATE397097T1 (de) 1995-03-17 2008-06-15 Wayne John Cancer Inst Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
JP4614472B2 (ja) * 1996-10-31 2011-01-19 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
EP0941328A1 (en) 1996-11-12 1999-09-15 Incyte Pharmaceuticals, Inc. Human breast tumor-specific proteins
WO1998033915A1 (en) 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Breast cancer specific gene 1
CA2291260A1 (en) 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
WO1998059049A1 (en) * 1997-06-20 1998-12-30 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO2000008210A1 (en) 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
JP2003518364A (ja) 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
EP1267934A4 (en) 1999-11-23 2004-03-17 Diadexus Inc NEW METHOD OF DIAGNOSIS, MONITORING, STATUS ASSESSMENT, IMAGE AND TREATMENT OF BREAST CANCER
JP5640237B2 (ja) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009155A1 (en) * 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 human secreted proteins
JP2002540761A (ja) * 1999-01-21 2002-12-03 アボット・ラボラトリーズ 乳房の疾患を検出するために有用な試薬と方法

Also Published As

Publication number Publication date
ZA200108065B (en) 2003-03-06
JP2010239970A (ja) 2010-10-28
ES2368899T3 (es) 2011-11-23
US20030229020A1 (en) 2003-12-11
US6590076B1 (en) 2003-07-08
ATE514780T1 (de) 2011-07-15
JP2002540789A (ja) 2002-12-03

Similar Documents

Publication Publication Date Title
EP1183348B1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
EP1169347B1 (en) Compounds and methods for therapy and diagnosis of lung cancer
EP1141290B1 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
JP2010239970A (ja) 乳癌の処置および診断のための組成物ならびにそれらの使用方法
JP2002540790A (ja) 肺癌の治療および診断のための化合物ならびにその使用のための方法
EP1097208A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
CA2383615A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
EP1715043A2 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001073027A2 (en) Compositions and methods for therapy and diagnosis of colon cancer
CA2460014A1 (en) Spas-1 cancer antigen
JP2002540789A5 (enExample)
WO2001051513A2 (en) Ovarian tumor-associated sequences
NZ567750A (en) Compositions and uses for cancer therapy
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
US6933363B1 (en) Compositions and methods for therapy and diagnosis of lung cancer
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
JP4942906B2 (ja) 卵巣癌の治療および診断のための組成物および方法
AU2007216683B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU2003271300B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2001027276A2 (en) Dna sequences from breast tumor and uses thereof
CA2613125A1 (en) Compositions and methods for therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070214

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080404

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100223

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110809

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110812

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees